These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8322487)

  • 1. Demonstration of protection in mice from a lethal challenge of three M serotypes of Streptococcus pyogenes using an M-negative vaccine.
    Chappell JD; Stuart JG
    Vaccine; 1993; 11(6):643-8. PubMed ID: 8322487
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced protection against Streptococcus pyogenes infection by intranasal vaccination with a dual antigen component M protein/SfbI lipid core peptide vaccine formulation.
    Olive C; Schulze K; Sun HK; Ebensen T; Horváth A; Toth I; Guzman CA
    Vaccine; 2007 Feb; 25(10):1789-97. PubMed ID: 17229503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal immunisation of mice with a streptococcal peptide-based vaccine.
    Relf W; Hayman W; Russell-Jones G; Good M
    Adv Exp Med Biol; 1997; 418():859-61. PubMed ID: 9331788
    [No Abstract]   [Full Text] [Related]  

  • 4. A new heart-cross-reactive antigen in Streptococcus pyogenes is not M protein.
    Barnett LA; Cunningham MW
    J Infect Dis; 1990 Oct; 162(4):875-82. PubMed ID: 1698206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group A streptococcal antigens and vaccine potential.
    Kehoe MA
    Vaccine; 1991 Nov; 9(11):797-806. PubMed ID: 1722063
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multivalent group A streptococcal vaccine designed to optimize the immunogenicity of six tandem M protein fragments.
    Dale JB
    Vaccine; 1999 Jan; 17(2):193-200. PubMed ID: 9987154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo efficacy of a chimeric peptide derived from the conserved region of the M protein against group C and G streptococci.
    Nordström T; Malcolm J; Magor G; Good MF; Batzloff MR
    Clin Vaccine Immunol; 2012 Dec; 19(12):1984-7. PubMed ID: 23081813
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine strategies to prevent rheumatic fever.
    Brandt ER; Good MF
    Immunol Res; 1999; 19(1):89-103. PubMed ID: 10374697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospects for a group A streptococcal vaccine.
    McMillan DJ; Chhatwal GS
    Curr Opin Mol Ther; 2005 Feb; 7(1):11-6. PubMed ID: 15732524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protection against streptococcal pharyngeal colonization with vaccines composed of M protein conserved regions.
    Fischetti VA; Bessen DE; Schneewind O; Hruby DE
    Adv Exp Med Biol; 1991; 303():159-67. PubMed ID: 1805563
    [No Abstract]   [Full Text] [Related]  

  • 11. Oral immunization of mice with engineered Lactobacillus gasseri NM713 strain expressing Streptococcus pyogenes M6 antigen.
    Mansour NM; Abdelaziz SA
    Microbiol Immunol; 2016 Aug; 60(8):527-32. PubMed ID: 27301486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenesis of group A streptococci in mice and efficacy of locally administered streptococcal vaccines.
    Bronze MS; McKinsey DS; Beachey EH; Dale JB
    Trans Assoc Am Physicians; 1988; 101():88-92. PubMed ID: 3077732
    [No Abstract]   [Full Text] [Related]  

  • 13. [Primary prevention of rheumatism: the status and outlook (vaccine)].
    Rotta Y
    Ter Arkh; 1985; 57(11):97-100. PubMed ID: 3909476
    [No Abstract]   [Full Text] [Related]  

  • 14. Systemic and mucosal immunizations with fibronectin-binding protein FBP54 induce protective immune responses against Streptococcus pyogenes challenge in mice.
    Kawabata S; Kunitomo E; Terao Y; Nakagawa I; Kikuchi K; Totsuka K; Hamada S
    Infect Immun; 2001 Feb; 69(2):924-30. PubMed ID: 11159987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mucosal vaccine made from live, recombinant Lactococcus lactis protects mice against pharyngeal infection with Streptococcus pyogenes.
    Mannam P; Jones KF; Geller BL
    Infect Immun; 2004 Jun; 72(6):3444-50. PubMed ID: 15155651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a multicomponent vaccine for Streptococcus pyogenes based on the antigenic targets of IVIG.
    Reglinski M; Lynskey NN; Choi YJ; Edwards RJ; Sriskandan S
    J Infect; 2016 Apr; 72(4):450-9. PubMed ID: 26880087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Location of variable and conserved epitopes among the multiple serotypes of streptococcal M protein.
    Jones KF; Manjula BN; Johnston KH; Hollingshead SK; Scott JR; Fischetti VA
    J Exp Med; 1985 Mar; 161(3):623-8. PubMed ID: 2579187
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus: S. pyogenes super-infection.
    Klonoski JM; Hurtig HR; Juber BA; Schuneman MJ; Bickett TE; Svendsen JM; Burum B; Penfound TA; Sereda G; Dale JB; Chaussee MS; Huber VC
    Vaccine; 2014 Sep; 32(40):5241-9. PubMed ID: 25077423
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protective efficacy of group A streptococcal vaccines containing type-specific and conserved M protein epitopes.
    Penfound TA; Chiang EY; Ahmed EA; Dale JB
    Vaccine; 2010 Jul; 28(31):5017-22. PubMed ID: 20546830
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of novel Streptococcus pyogenes vaccine candidates incorporating multiple conserved sequences from the C-repeat region of the M-protein.
    Bauer MJ; Georgousakis MM; Vu T; Henningham A; Hofmann A; Rettel M; Hafner LM; Sriprakash KS; McMillan DJ
    Vaccine; 2012 Mar; 30(12):2197-205. PubMed ID: 22265945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.